

**Anti-NKG2D / CD314 Reference Antibody (tesnatilimab)
Recombinant Antibody
Catalog # APR10241****Specification**

Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) - Product Information

Application	FC, E, FTA
Primary Accession	P26718
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG4
Calculated MW	143.9 KDa

Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) - Additional Information**Target/Specificity**
NKG2D / CD314**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) - Protein Information****Name** KLRK1**Synonyms** D12S2489E, NKG2D**Function**
Functions as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress- inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. Stimulates perforin-mediated elimination of ligand-expressing tumor

cells. Signaling involves calcium influx, culminating in the expression of TNF-alpha. Participates in NK cell- mediated bone marrow graft rejection. May play a regulatory role in differentiation and survival of NK cells. Binds to ligands belonging to various subfamilies of MHC class I-related glycoproteins including MICA, MICB, RAET1E, RAET1G, RAET1L/ULBP6, ULBP1, ULBP2, ULBP3 (ULBP2>ULBP1>ULBP3) and ULBP4.

Cellular Location

Cell membrane; Single-pass type II membrane protein Note=Colocalized with HCST on the cell surface

Tissue Location


Expressed in natural killer (NK) cells, CD8(+) alpha-beta and gamma-delta T-cells. Expressed on essentially all CD56+CD3- NK cells from freshly isolated PBMC. Expressed in interferon- producing killer dendritic cells (IKDCs).

Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) - Images



Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) is more than 100%, determined by SEC-HPLC.



Immobilized human NKG2D His at 2 µg/mL can bind Anti-NKG2D / CD314 Reference Antibody (tesnatilimab) $EC_{50}=0.0209$ µg/mL